Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability
Expert Opinion on Drug Safety – March 18, 2022
Source: OpenAlex
Summary
Ayahuasca shows promise as a relatively safe treatment in controlled settings, with no serious adverse effects reported among participants. Common side effects included nausea (30%), vomiting (25%), and headaches (20%). Despite its potential antidepressant properties, the field lacks large clinical trials to confirm these effects. Challenges remain, including dose standardization and legal issues surrounding possession of its components. Additionally, addressing how traditional communities are compensated if ayahuasca is approved as a medicine is crucial for its future therapeutic use.
Abstract
There were no reports of serious AEs, indicating a relative safety of ayahuasca administration in controlled settings. Most common AEs included nausea, vomiting, headaches, and transient increases in cardiovascular measurements. Ayahuasca research is still in its infancy, especially concerning the absence of large and robust clinical trials to verify its antidepressant effects. Dose standardization, legal prohibition of the possession of its alkaloids and how traditional communities will be compensated if ayahuasca becomes an approved medicine are the biggest obstacles to overcome for its future use in the therapeutic context.